Research & Policy

Public Testimony

2022, House Judiciary Committee Hearing for HB 1393 (Rep. Struzzi) Help Prevent Overdose Deaths: Invited to present testimony to legislators re: drug checking, fentanyl test strips decriminalization.

Transcript. Submitted Testimony. Recorded Hearing.

2016, House Resolution 590 Task Force Hearing: Access to Addiction Treatment: MAT for opioid use disorders. Presented on lack of access in jails and drug courts, October 2016

Journal Articles

Leslie W. Suen, Michael Incze, Caty Simon, Honora Englander, Jeffrey Bratberg, Gail Groves Scott, and Rachel Winograd. 2024. “Methadone’s Resurgence in Bridging the Treatment Gap in the Overdose Crisis: Position Statement of AMERSA, Inc (Association for Multidisciplinary Education, Research, Substance Use, and Addiction).” Substance Use & Addiction Journal 29767342241255480. doi: 10.1177/29767342241255480 (https://doi.org/10.1177/29767342241255480)
.

Policy Briefs & White Papers

2019 Policy Brief: Expanding the DEA Opioid Treatment Program “hospital waiver”: increasing access to buprenorphine and methadone in all residential facilities, from hospitals to jails and nursing homes

White Paper, 2020: X-ray Transmission Body Scanners in U.S. Correctional Facilities: Policy Analysis

White Paper, 2016: Forced withdrawal in jails for methadone and buprenorphine patients: Policy analysis and recommendations; Policy Brief, 2016: Ending Forced Withdrawal in Jails (MPH Capstone Project, unpublished)

Research Posters and Presentations

“Ethical questions arising from the evolution of prescriber targeting in pharmaceutical sales” (Poster) (Citations)

Poster presented at American Public Health Association (APHA), Nov. 2022 Annual Conference, Boston, MA

“A Prescription Drug Illegal Marketing Case: ‘Dead Baby’ Messaging, a Billion-Dollar ‘Product Hop’ and the Buprenorphine Public Health Campaign That Wasn’t” (Slides_19pp) (Abstract & Citations.)

Oral Abstract Presentation: AMERSA (The Association for Multidisciplinary Education and Research in Substance use and Addiction) Nov. 2022 46th Annual Conference, Boston, MA

“When Pharmacovigilance and Pharmaceutical Marketing Intersect: Sales Reps, “Pill Mills” and Policy Gaps”

Oral Abstract Presentation: PharmedOut 2021 International Virtual Conference: Cutting the Cord: Curtailing Commercial Influence on Healthcare. Conference program p.14, June, 15, 2021

“Implementing buprenorphine pharmacotherapy in a large urban jail system, Philadelphia Department of Prisons, 2018-2019” co-authored with Bruce Herdman, PhD, and Jon Lepley, DO;

Poster presentation, Nov. 2019, Association for Medical Education & Research in Substance Abuse (AMERSA) National Conference, Boston, MA

“Pharmacists can provide MAT: a long-acting injectable naltrexone clinic in rural KY”

Oral Abstract Presentation: AMERSA (The Association for Multidisciplinary Education and Research in Substance use and Addiction) Nov. 2018 National Conference, San Francisco, CA.
Poster presented at American Association for the Treatment of Opioid Dependence (AATOD) March 2018 Conference, New York City.

“An examination of opioid use disorder treatment policies in two criminal justice settings in South-Central PA”

Poster presentation (revised), Nov. 2017 Association for Medical Education & Research in Substance Abuse (AMERSA) National Conference, Washington, DC.
Poster presentation, The Penn State Addictions Symposium, Hershey, PA, May 2016.

Selected Conference Presentations

“Shattering the Stigma and Ending the Shame”, co-presenting with Brooke Feldman, MSW; AATOD (American Association for Treatment of Opioid Dependence) National Conference, Orlando, FL, Sept. 2019

“Therapeutic Use of Cannabis: Facts, Myths, & Policy Considerations, co-presenting with Christine Roussel, PharmD, BCOP; AATOD, National Conference, Orlando, FL, Sept. 2019

“Pharma Sales and the Evolution of Prescriber ‘Targeting,’” 2019 PharmedOUT Conference on Opioids: Conflicts & Controversies, June 2019

“Older People Don’t Do Drugs, Do They?” College of Physicians of Philadelphia, Senior Health Forum, April 2018

“Medical Cannabis: An Emerging Topic for CME & Science Writers”, American Medical Writer’s Association, Delaware Valley Chapter, April 2018, co-presenter: Cathleen O’Connor, RPh, PhD.

“Public Policy and Access to Recovery Housing for Persons on Medications for Opioid Use Disorder”, AATOD National Conference, New York, NY, March 2018

“The Opioid Crisis & Overdose Reversal Training, w/ Project Lazarus Lancaster County”, Millersville University, PA, February 2018

Presenter & Moderator for Panel: “Making the Connections: Medical Cannabis and Its Impact on Opioid Use,” University of the Sciences, Philadelphia PA, March 2018

Moderator: “Making Connections: Policymakers Address the Opioid Epidemic,” University of the Sciences, Philadelphia PA, March 2017

“Opioid Use Disorder: Evidence-Based Treatment & Overdose Prevention”: Case Manager Association of Central PA, Danville, PA, October 2016

“OUD Treatment Policies in Justice System Settings in PA”: RCPA Criminal Justice subcommittee, Sept. 2016.